Back to search results

Understanding Ventricular Tachycardia with MAP Catheter

This study aims to better understand why some hearts develop ventricular tachycardia (VT), a fast, abnormal heart rhythm. Researchers are using a special device called the Monophasic Action Potential (MAP) Catheter during a standard VT ablation procedure. This catheter helps study the electrical signals of heart tissue in detail, which isn't possible with traditional methods. By examining these signals, the study hopes to identify areas of the heart that cause VT and ultimately improve the success of VT ablation treatments. You may be able to join if you have ischemic cardiomyopathy (a type of heart disease) and an implantable cardioverter-defibrillator (ICD). The study is looking for about 10 participants, but its current status is unclear.

Study design
This is an interventional study, meaning you will receive a specific intervention. It plans to enroll about 10 participants.
What's involved
During a standard VT ablation, the MAP catheter will be used to record electrical signals from your heart. The study measures waveform morphology and conduction velocity on Day 1 during the ablation.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints (what the study measures) are taken during the ablation on Day 1. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05478213

Ventricular Tachycardia Mechanisms

Recruiting
NAAges 18+InterventionalBasic science
Emory University
~10 participants
Updated 2026-06-30 on ClinicalTrials.gov
What's tested:Monophasic Action Potential (MAP) Catheter

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Waveform Morphology
Measured over During ablation on Day 1
+1 more outcome measured

Conditions

Ventricular Tachycardia

Explore related trials

Generalized ischemic myocardial dysfunctionVentricular Tachycardia

Where it's being run

3 sites across 1 states
Georgia3

Study leadership

  • Neal Bhatia, MD · PRINCIPAL_INVESTIGATOR · Emory University

Who to contact

Neal Bhatia, MD
[email protected]
404-686-7878
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of ischemic cardiomyopathy
Single or dual chamber implantable cardioverter-defibrillator (ICD)

Exclusion

Non-Ischemic cardiomyopathy
Contraindication to catheter ablation
Severe peripheral arterial disease or medical condition that prohibit arterial access
Ventricular tachycardia (VT) or sudden cardiac arrest (SCA) within 30 days of acute coronary syndrome or within 90 days of coronary revascularization

What this trial measures

  • Waveform MorphologyDuring ablation on Day 1

    Identification of sites that are critical to reentry of ventricular tachycardia from bystander sites will be performed by analyzing local ventricular activation. Local ventricular action is assessed with waveform morphology and is measured in voltage (mV). The normal range is \>3 mV bipolar and \>8.3 mV unipolar.

  • Conduction VelocityDuring ablation on Day 1

    Identification of sites that are critical to reentry of ventricular tachycardia from bystander sites will be performed by analyzing electrophysiological properties. Electrophysiological properties are assessed with conduction velocity, measured in meters per second (m/s).